在罕见和难治性肿瘤的药物开发中平衡风险与效率:胶质瘤的新范式
本文以胶质瘤为例,讨论罕见和难治性实体瘤(如胶质瘤或胰腺癌)的临床药物开发与常见肿瘤不同,提出应建立更可靠的早期药物活性信号获取流程,并将这些信号更高效地转化为晚期临床获益;若两个流程衔接,有望以更低成本提高晚期获益可能性并鼓励更多药物开发。
要点
- 罕见和难治性实体瘤(如胶质瘤或胰腺癌)的临床药物开发与常见肿瘤存在根本差异。
- 应以胶质瘤为例建立更可靠的早期药物活性信号获取流程。
- 应将早期信号更高效地转化为晚期临床获益,若衔接可提高晚期获益可能性并降低成本。
核心结论
- 以胶质瘤为例,建立更可靠的早期药物活性信号获取流程并将这些信号更高效地转化为晚期临床获益,若两个流程衔接,应能提高晚期获益可能性、降低成本并鼓励更多药物开发。
研究设计与样本
- 本文为以胶质瘤为例的方法学论述,未报告系统检索范围或样本量。
主要发现
- 常见肿瘤的癌症治疗药物开发流程已成熟,使许多新药及新类别药物进入标准治疗。
- 罕见和难治性实体瘤(如胶质瘤或胰腺癌)的临床药物开发与常见肿瘤存在根本差异。
- 针对后一类疾病未能开发出有效新药,抑制了针对这些癌症的治疗开发。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The process of developing cancer therapies is well established and has enabled the incorporation of many new drugs and classes of agents into the standard of care for common cancers. Clinical drug development is fundamentally different for rare and difficult-to-treat solid tumors, such as glioma or pancreatic cancer. The failure to develop effective new agents for the latter diseases has discouraged the development of therapeutics for these cancers. Using glioma as an example, we describe a process toward obtaining more reliable early-stage signals of drug activity and a process toward translating those signals into clinical benefits with more efficient late-stage development. If linked together, these processes should increase the likelihood of benefit in late-stage settings at a lower cost and encourage more drug development for patients with rare and difficult-to-treat cancers.
引用
- Mellinghoff IK, Cloughesy TF. Balancing Risk and Efficiency in Drug Development for Rare and Challenging Tumors: A New Paradigm for Glioma. J Clin Oncol. 2022. PMID: 35201903. doi:10.1200/JCO.21.02166
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。